Bronchiectasis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Bronchiectasis – Pipeline Review, H1 2020’, provides an overview of the Bronchiectasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Bronchiectasis

– The report reviews pipeline therapeutics for Bronchiectasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Bronchiectasis therapeutics and enlists all their major and minor projects

– The report assesses Bronchiectasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Bronchiectasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bronchiectasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alitair Pharmaceuticals Inc

Chiesi Farmaceutici SpA

Helperby Therapeutics Group Ltd

Insmed Inc

Kamada Ltd

Novabiotics Ltd

OrPro Therapeutics Inc

Parion Sciences Inc

Polyphor AG

Recipharm AB

Santhera Pharmaceuticals Holding AG

Savara Inc

Therapeutic Systems Research Laboratories Inc

Zambon Co SpA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchiectasis - Overview

Bronchiectasis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bronchiectasis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchiectasis - Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

Chiesi Farmaceutici SpA

Helperby Therapeutics Group Ltd

Insmed Inc

Kamada Ltd

Novabiotics Ltd

OrPro Therapeutics Inc

Parion Sciences Inc

Polyphor AG

Recipharm AB

Santhera Pharmaceuticals Holding AG

Savara Inc

Therapeutic Systems Research Laboratories Inc

Zambon Co SpA

Bronchiectasis - Drug Profiles

alpha-1 proteinase inhibitor (human) second generation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amikacin sulfate PR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brensocatib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHF-6333 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxofylline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdosteine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HY-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

murepavadin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCFBE-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORP-100S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-6014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bronchiectasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tobramycin + triclosan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchiectasis - Dormant Projects

Bronchiectasis - Discontinued Products

Bronchiectasis - Product Development Milestones

Featured News & Press Releases

Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis

Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference

Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions

May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007

Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA

Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis

Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product

Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis

Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bronchiectasis, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Bronchiectasis – Pipeline by Alitair Pharmaceuticals Inc, H1 2020

Bronchiectasis – Pipeline by Chiesi Farmaceutici SpA, H1 2020

Bronchiectasis – Pipeline by Helperby Therapeutics Group Ltd, H1 2020

Bronchiectasis – Pipeline by Insmed Inc, H1 2020

Bronchiectasis – Pipeline by Kamada Ltd, H1 2020

Bronchiectasis – Pipeline by Novabiotics Ltd, H1 2020

Bronchiectasis – Pipeline by OrPro Therapeutics Inc, H1 2020

Bronchiectasis – Pipeline by Parion Sciences Inc, H1 2020

Bronchiectasis – Pipeline by Polyphor AG, H1 2020

Bronchiectasis – Pipeline by Recipharm AB, H1 2020

Bronchiectasis – Pipeline by Santhera Pharmaceuticals Holding AG, H1 2020

Bronchiectasis – Pipeline by Savara Inc, H1 2020

Bronchiectasis – Pipeline by Therapeutic Systems Research Laboratories Inc, H1 2020

Bronchiectasis – Pipeline by Zambon Co SpA, H1 2020

Bronchiectasis – Dormant Projects, H1 2020

Bronchiectasis – Dormant Projects, H1 2020 (Contd..1), H1 2020

Bronchiectasis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Bronchiectasis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports